Sessions & Presentations

The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro
Poster Area
12. April 2019, 09:00 AM - 05:00 PM More ...
Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial
Main Plenary
12. April 2019, 10:15 AM - 10:30 AM More ...
The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro
Meeting point 1
12. April 2019, 11:00 AM - 11:30 AM More ...

Abstracts

Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial Late Breaker More ... Abstract
The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro Viral hepatitis B/D: therapy More ... Abstract